Last reviewed · How we verify
FOLFOX chemotherapy regimen
FOLFOX is a combination chemotherapy regimen that kills cancer cells by damaging DNA and preventing cell division through multiple mechanisms of action.
FOLFOX is a combination chemotherapy regimen that kills cancer cells by damaging DNA and preventing cell division through multiple mechanisms of action. Used for Metastatic colorectal cancer, Adjuvant treatment of stage III colorectal cancer, Advanced gastric cancer.
At a glance
| Generic name | FOLFOX chemotherapy regimen |
|---|---|
| Also known as | CapeOx chemotherapy regimen |
| Sponsor | Sixth Affiliated Hospital, Sun Yat-sen University |
| Drug class | Combination chemotherapy regimen |
| Target | Thymidylate synthase (5-FU), DNA (oxaliplatin) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
FOLFOX combines three drugs: 5-fluorouracil (5-FU), which inhibits thymidylate synthase and disrupts DNA synthesis; leucovorin (folinic acid), which enhances 5-FU's activity by stabilizing its binding to target enzymes; and oxaliplatin, a platinum compound that forms DNA crosslinks and prevents replication. Together, these agents work synergistically to induce apoptosis in rapidly dividing cancer cells.
Approved indications
- Metastatic colorectal cancer
- Adjuvant treatment of stage III colorectal cancer
- Advanced gastric cancer
- Pancreatic cancer
Common side effects
- Neutropenia
- Anemia
- Thrombocytopenia
- Nausea and vomiting
- Diarrhea
- Peripheral neuropathy
- Mucositis
- Fatigue
Key clinical trials
- Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial) (PHASE2)
- Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer (PHASE1)
- HAIC Plus Systemic Therapy as De-escalation Therapy Strategy for Biliary Tract Cancer (NA)
- A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer (PHASE2, PHASE3)
- Combination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Esogastric Adenocarcinomas (PHASE3)
- Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays (NA)
- Perioperative Systemic Therapy for Isolated Resectable Colorectal Peritoneal Metastases (PHASE2, PHASE3)
- Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: